（文章来源：证券日报） 证券日报网讯 8月21日晚间，华康股份发布公告称，2025年半年度公司实现营业收入1，865，861， 711.37元，同比增长37.32%；归属于上市公司股东的净利润为133，705，194.39元，同比下降3.38%。 ...

（文章来源：证券日报） 证券日报网讯 8月21日晚间，华康股份发布公告称，公司第六届监事会第二十一次会议审议通过了《关 于公司2025年半年度报告及其摘要的议案》等多项议案。 ...

证券日报网讯 8月21日晚间，华康股份发布关于公司2025年中期利润分配预案的公告称，公司拟向全体 股东每10股派发现金红利2元（含税），截至2025年8月20日公司总股本为30，304.9751万股，以此计算 拟分配的股本，拟派发现金红利6，060.99502万元（含税），本年度公司现金分红占公司2025年半年度 归属于上市公司股东净利润的比率为45.33%。 （编辑 任世碧） ...

Core Viewpoint - Huakang Co., Ltd. reported a revenue of 1.866 billion yuan for the first half of 2025, marking a year-on-year increase of 37.32%, while the net profit attributable to shareholders decreased by 3.38% to 134 million yuan [1] Financial Performance - The company achieved an operating income of 1.866 billion yuan, reflecting a growth of 37.32% compared to the previous year [1] - The net profit attributable to shareholders was 134 million yuan, which represents a decline of 3.38% year-on-year [1] - Basic earnings per share stood at 0.45 yuan [1] Dividend Distribution - The company plans to distribute a cash dividend of 2 yuan (including tax) for every 10 shares to all shareholders [1] Factors Affecting Performance - The decline in net profit is primarily attributed to the increase in liquid product business in Zhoushan, changes in the sales product structure leading to a decrease in gross margin, and increased financial expenses due to the capitalization of convertible bond interest [1]

Group 1 - The company Huakang Co., Ltd. (SH 605077) announced the convening of its 32nd meeting of the 6th Board of Directors on August 21, 2025, which was held in a hybrid format of in-person and communication [2] - The meeting reviewed the proposal regarding the company's half-year report for 2025 and its summary [2] - For the year 2024, the company's revenue composition indicates that the agricultural and sideline food processing industry accounted for 99.51% of total revenue, while other businesses contributed 0.49% [2]

Core Viewpoint - Huakang Co., Ltd. reported a significant increase in revenue for the first half of 2025, while net profit experienced a slight decline compared to the previous year [2] Financial Performance - The company's operating revenue for the first half of 2025 was approximately 1.866 billion yuan, representing a year-on-year increase of 37.32% [2] - The net profit attributable to shareholders of the listed company was around 134 million yuan, showing a year-on-year decrease of 3.38% [2] - Basic earnings per share were 0.45 yuan, which is a decrease of 2.17% year-on-year [2]

Core Viewpoint - Zhejiang Huakang Pharmaceutical Co., Ltd. plans to distribute a cash dividend of 2 yuan (including tax) for every 10 shares, based on the total share capital registered on the equity distribution date [1][2]. Summary by Sections Profit Distribution and Capital Increase Plan - As of June 30, 2025, the company has a distributable profit of 1,174.4735 million yuan [1]. - The proposed cash dividend distribution is based on the total share capital as of the equity distribution registration date, which is 30,304.9751 million shares as of August 20, 2025 [1]. - The cash dividend represents 45.33% of the company's net profit attributable to shareholders, with no capital increase from reserves planned [1]. Decision-Making Process - The company held the 32nd meeting of the sixth board of directors and the 21st meeting of the sixth supervisory board on August 21, 2025, where the profit distribution proposal was approved [2]. - The supervisory board believes the profit distribution plan considers the company's operational and financial status and aligns with relevant regulations, supporting sustainable development without harming the interests of the company and investors [2]. Additional Notes - If there are changes in total share capital due to convertible bonds, share buybacks, or other factors before the equity distribution registration date, the per-share distribution ratio will remain unchanged, and the total distribution amount will be adjusted accordingly [2]. - The profit distribution proposal is subject to approval at the company's second extraordinary general meeting of shareholders in 2025 [2].

浙江华康药业股份有限公司 二○二五年八月 浙江华康药业股份有限公司 第一章 总 则 第一条 为保证浙江华康药业股份有限公司（以下简称"公司"）及子公司 的对外担保管理，规范公司担保行为，控制经营风险，根据《中华人民共和国 公司法》《中华人民共和国证券法》《上市公司监管指引第 8 号——上市公司 资金往来、对外担保的监管要求》《上海证券交易所股票上市规则》《上海证 券交易所上市公司自律监管指引第 1 号——规范运作》等法律法规及《浙江华 康药业股份有限公司章程》（以下简称"《公司章程》"）的有关规定，制定 本制度。 第三条 本制度适用于本公司及子公司，子公司发生对外担保，按照本制度 执行。 第四条 子公司在对外担保事项递交其董事会或股东会审议之前，应提前 5 个工作日向公司进行书面申报，并在其董事会或股东会做出决议当日书面通知 公司董事会办公室履行相关信息披露义务。 第五条 公司对外担保应当遵循合法、审慎、互利、安全的原则，严格控制 担保风险。 第二章 对外担保的决策权限 第六条 对外担保事项必须由董事会或股东会审议。 第 1 页 共 6 页 第七条 董事会审议对外担保事项时，除应当经全体董事的过半数通过外， ...

浙江华康药业股份有限公司 二○二五年八月 浙江华康药业股份有限公司 第一章 总 则 第一条 为加强浙江华康药业股份有限公司（以下简称"公司"）对外投资 的管理，规范公司对外投资行为，提高投资效益，合理、有效地使用资金，依 照《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证券交易 所股票上市规则》（以下简称"《股票上市规则》"）等法律法规和《浙江华 康药业股份有限公司章程》（以下简称"《公司章程》"）的相关规定，制定 本制度。 第二条 本制度所称对外投资是指公司为了通过分配来增加财富，或谋求其 他利益，将公司拥有的资产让渡给其他单位而获得另一项资产的活动。 按照投资目的分类，对外投资分为短期投资和长期投资。短期投资包括股 票投资和债券投资等以短期财务收益为目标的投资，长期投资包括长期股权投 资和长期债权投资等以股权控制、资产占有、长期收益等长期利益为目标的投 资。 第三条 投资管理应遵循的基本原则：公司对外投资行为必须符合国家有关 法规及产业政策，符合公司发展战略，有利于增强公司竞争能力，有利于合理 配置企业资源，创造良好经济效益，促进公司可持续发展。 第二章 对外投资的职责分工 第四条 公司投资部 ...

General Provisions - The company establishes rules to regulate its behavior and ensure shareholders can exercise their rights according to the Company Law and Securities Law [1][2] - The board of directors is responsible for organizing shareholder meetings and ensuring they are held in accordance with legal requirements [1][2] Shareholder Meeting Types - Shareholder meetings are categorized into annual and extraordinary meetings, with annual meetings held within six months after the end of the previous fiscal year [1][2] - Extraordinary meetings must be convened within two months under specific circumstances, such as insufficient board members or significant losses [1][2][3] Meeting Convening and Proposals - The board must convene meetings within the stipulated time and must respond to independent directors' requests for extraordinary meetings within ten days [2][3][4] - Shareholders holding more than 10% of shares can request extraordinary meetings, and the board must respond within ten days [4][5] Meeting Notifications - Notifications for annual meetings must be sent at least twenty days in advance, while extraordinary meetings require a fifteen-day notice [6][7] - Notifications must include details such as meeting time, location, agenda, and rights of shareholders to attend and vote [6][7] Voting Procedures - Shareholders can vote in person or by proxy, and the voting process must be clearly outlined in the meeting notification [8][9] - The company must ensure that all shareholders can participate in the voting process, including through online methods [8][9] Meeting Conduct - The chairman of the board presides over the meeting, and if unavailable, a vice-chairman or a designated director will take over [11][12] - Shareholders have the right to question directors and senior management during the meeting, with specific conditions under which questions may be refused [11][12] Voting Results and Announcements - Voting results must be announced immediately after the meeting, detailing the number of shareholders present and the voting outcomes for each proposal [15][16] - The company is required to disclose the results of the voting and any resolutions passed in a timely manner [15][16] Record Keeping - Meeting records must be maintained for ten years and should include details such as meeting time, participants, and voting results [16][17] - The company must ensure that all documentation related to the meeting is accurate and complete [16][17] Miscellaneous Provisions - The rules are effective upon approval by the shareholder meeting and can be modified as necessary [18] - The board of directors is responsible for interpreting these rules [18]